drugset
Drugs / VEROSUDIL
last change Feb 2015 re-read 9 days ago

VEROSUDIL

also known as AR-12286 · AR-12286 FREE BASE · VEROSUDIL HYDROCHLORIDE

Small molecule

Developed for
ocular hypertension · glaucoma · open-angle glaucoma · chronic closed-angle glaucoma · exfoliation syndrome
Investigated by
Aerie Pharmaceuticals · New York Glaucoma Research Institute · Robert Ritch, MD, LLC.

Trials 12

today NCT02174991 · Ph 2 NCT02173223 · Ph 2 NCT02152774 · Ph 2 NCT01936389 · Ph 2 NCT01789736 · Ph 2 NCT01699464 · Ph 2 NCT01474135 · Ph 2 NCT01330979 · Ph 2 NCT01302249 · Ph 2 NCT01250197 · Ph 1 NCT01060579 · Ph 2 NCT00902200 · Ph 2
2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT01250197 Nov → Dec 2010 — Aerie Pharmaceuticals Completed No outcome recorded
Phase 211 trials · 1 met primary
Phase 2 NCT02174991 Jun 2014 → Feb 2015 glaucoma New York Glaucoma Research Institute Unknown No outcome recorded
Phase 2 NCT02173223 Jun 2014 → Feb 2015 glaucoma New York Glaucoma Research Institute Unknown No outcome recorded
Phase 2 NCT02152774 May 2014 → Feb 2015 chronic closed-angle glaucoma New York Glaucoma Research Institute Unknown No outcome recorded
Phase 2 NCT01936389 Sep 2013 → Oct 2014 exfoliation syndrome, ocular hypertension, open-angle glaucoma Robert Ritch, MD, LLC. Completed No outcome recorded
Phase 2 NCT01789736 Feb → Jun 2013 ocular hypertension, open-angle glaucoma Aerie Pharmaceuticals Completed No outcome recorded
Phase 2 NCT01699464 Oct 2012 → Apr 2013 ocular hypertension, open-angle glaucoma Aerie Pharmaceuticals Completed No outcome recorded
Phase 2 NCT01474135 Dec 2011 → Apr 2012 glaucoma, ocular hypertension Aerie Pharmaceuticals Completed No outcome recorded
Phase 2 NCT01330979 May 2011 → Aug 2012 ocular hypertension, open-angle glaucoma Aerie Pharmaceuticals Completed No outcome recorded
Phase 2 NCT01302249 Feb → Dec 2011 glaucoma, ocular hypertension Aerie Pharmaceuticals Completed No outcome recorded
Phase 2 NCT01060579 Feb → Aug 2010 glaucoma Aerie Pharmaceuticals Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

FieldValueCited text
Known as VEROSUDIL ChEMBL registry synonym — accepted as the source's own label CHEMBL3545065 ↗
Known as AR-12286 “AR-12286 is a novel, potent Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ.” NCT02152774 ↗
11

“AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ.” NCT02173223 ↗

NCT02174991 ↗

NCT01302249 ↗

NCT01936389 ↗

NCT01060579 ↗

NCT01699464 ↗

NCT01250197 ↗

NCT00902200 ↗

NCT01474135 ↗

NCT01330979 ↗

Show 1 more source
Known as AR-12286 FREE BASE ChEMBL registry synonym — accepted as the source's own label CHEMBL3545065 ↗
Known as VEROSUDIL HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL3545065 ↗
Action Inhibit “Rho kinase inhibitor AR-12286” PMID 21794845 ↗ Jul 2011
Modality Small molecule — CHEMBL3545065 ↗
Route Topical “topical AR-12286” NCT01060579 ↗